Brought to you by 
Grunenthal to sell Labopharm's pain drug in France
13 Jun 2006
Executive Summary
Specialty pharma Labopharm licensed Grunenthal (develops and markets pain treatments) semi-exclusive French marketing rights to its once-daily centrally acting analgesic tramadol. Grunenthal shares rights with Sanofi-Aventis in this territory.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Grunenthal to sell Labopharm's pain drug in France
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice